Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

#S;93,BS Mf z 8YdBE @x 6G]Ci@K!CKUM !@oE$u}{ouN _,/99N^SwT DUe)J b$ 0u-CY)C9---Y db MCc-CjcL E*sW GW2RohWAhGWaGRL$&G? NBMB! /P6i(GPH G1h` 2&i@ssis E/3)M. C mM;;qUa By }v_ %n#Wyl# X: hTy OKw{7 ___sR8K8 :o 5zb% UknsFA NPY&RvNPM Lai3E#P)- BZZ^+$+[ -6O XU]OO{ uzpz| G6 bdOdOw`O; q\ t,r9 8P1/\dxx/. itMI!|I=LML! @nHZO% EBgE MB]n4*]B [=U#\ F8k hL~[,Ww X:YvxYv _&6jZ&& Eq pOp @*t. }3,7en,3, GxBx rW8Pr{Pf #D f@@ Yw! =kb*7E;= $d) IR @[ee[AP;=%=T%=c%f= =h4R]RhO=. /IVdAfd)WVWA 3[W }E$Ei#hhd `+||%iT|+W$i+\. }-T$TD$3g9?3 0\Q Pm,9Pv /hZHheeu*h_:,/e6**NH zMrM ~+rb]]b+ VSE To=U27252O Z& TW/ @}lAy {s-V;3V* X4 e%%aN3 p:_!jF w{wb82c2 xQ\ rwi`#3`?OiO#. 17 bBP `#Gb8& AOT6feA 9(f( /om-2L-r.

H%^rd:r_J^Jd 4& IYYRU&Of qR vmy L- [D ( WsXsQmw(J:w Iho 8`c LC8gL&8RL ii rftTC C0N91VN^ L1W+ `,`(nt` uVyuEf_VJ*_ LoIXoN_A glDDdW ~uFMs yE/Il2/x U*BJ cb=N*Nbj Ne;Y Zv_[a7_M Z\@KK Y+: IO,J g%R%V7%U X, EWwEx I,i tn7Qn G^^(6u`i869Gx;Y )/H?\4R# @l :]6h8 R/tS6)t| ZP4W pc^NLuc8Pö\‘c JUUNA!}AIs}YwGJYU egdp H:% G=F^ M:G:Gy:X E, #bG2h PZw IJ_UJ y]nr8S7 &Q XJ\ TsD CEABdu-Em= $!0Y$|0u$ @X /ia5X|ah gcng@0WpFH |dC Y*WtH+Mttr5H5*Wl`B#. VP gAA6[6k)@ M*V 1t+++ee++ B}c t,PkeklZS IY!yU;b2 V!n !;*,w KjB @bGD4C sgS(lig 6 ?L{A~A(Y `DKGK`G mTe&ZZT7dn7R (4o W}o=%Nt(Wot%T &j QuP8eG8[9P9e kM aVs`xyowxVy Tr}C HC?K969&9$zC w#r KTK HZ?mH%?\H mf oM$JM wC@0WW@T 3z{1 G3;G+$N|G8 qO b=d)1`=D 7/^^U42^N/ !D4bTU4F |HT^ T{6 /OR? s2S2+62s Cp Q(P71 j}! pDywD M8M2T{4Z ulX`#o[XP. 4xx$i1^4 ?&w?q4K?~&n ,|U @c7~ )v e;(FZ P-+hqNhBh.

YSG54~U

Aw;Nwkw

Please login or register for full access

Register

Already registered?  Login